Boehringer's innovative injectable medication maintains muscle mass while significantly decreasing visceral fat accumulation effectively. Those suffering from fatty liver disease demonstrate noticeable improvements as well.
ReadA 70-year-old Texas feedlot's very existence hangs in the balance due to potential border closures affecting cattle imports from Mexico.
Robert F. Kennedy Jr., the Health Secretary, is reportedly not actively overseeing his department's vast operations, instead concentrating on initiatives related to food and vaccines.
Renowned child psychiatrist Dr. Robert Coles's five-volume "Children of Crisis" series spanned a decade, from 1967 to 1977, featuring unheard American youth voices.
Eli Lilly has secured a significant partnership with Ascidian Therapeutics, licensing the company's cutting-edge gene-editing tech for a potential $1.9 billion investment in novel treatments for rare genetic kidney disorders.
Experts attribute the surge in cancer survival rates to targeted therapies' effectiveness. Long-term survivors like Smithwick and Vacca demonstrate the success of innovative cancer treatments.
Medtronic's quarterly performance is exceeding expectations, with revenue projected to surpass $2027 estimates due to strategic partnerships. Separation of the diabetes division remains a flexible goal.
According to a recent statement from Eli Lilly's CEO, the company is significantly scaling back its German investment plan, which was initially set at €2.3 billion.
A warning letter was recently sent by the U.S. FDA to Medline, citing non-compliance with manufacturing quality regulations, marking their second infraction within a two-month timeframe.
The Ebola outbreak in the DRC has shown notable improvement, despite concerns it began as far back as January. The testing backlog is decreasing, albeit slowly, with approximately 45% of identified contacts successfully tracked by health au
The US government has yet to confirm whether individuals exposed to Ebola will be permitted re-entry under standard protocols for repatriation and medical surveillance.
Everest Medicines, a privately held biotech company, has partnered with Travere Therapeutics to bring a novel kidney disease treatment to market under a licensing agreement valued at up to $1.14 billion.
Philip Morris International has trimmed its projected annual profits due to currency fluctuations, while CEO Jacek Olczak noted that other potential roadblocks are currently under control.
The day's signal, decoded by our editors and shipped before your first coffee. We'll email a one-tap confirmation link to verify your address.
